Information  X 
Enter a valid email address

Omega Diagnostics Gp (ODX)


Tuesday 15 June, 2021

Omega Diagnostics Gp

Statement re. Media Comment

RNS Number : 9486B
Omega Diagnostics Group PLC
15 June 2021


("Omega" or the "Company" or the "Group")


Statement re. Media Comment


Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes the recent media comment that Mologic Ltd have requested for Porton Down to evaluate their lateral flow antigen test with an independent party observing.


This process has no implications on the UK Government manufacturing contract that Omega has in place with the Department of Health and Social Care ("DHSC"). Under that contract Omega will provide manufacturing capacity for COVID-19 lateral flow antigen tests utilising the key pieces of manufacturing equipment loaned by the UK Government for that purpose and Omega will manufacture whichever test is approved for use by the DHSC. As clarified on 7 June 2021 the ability to supply tests that are produced within the UK remains a key priority for the DHSC and to that end the DHSC have facilitated initial commercial discussions between Omega and a number of companies with lateral flow antigen tests to potentially provide UK manufacturing services.


As already announced on 8 June 2021 Omega is in the process of seeking CE marking of its VISITECT® COVID-19 Antigen test, as a self-test. Final preparations for a submission to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) for this test is also underway.


Recently published study data confirms that Mologic's lateral flow antigen test, being commercialised by Omega as the VISITECT® COVID-19 Antigen test , demonstrates high diagnostic accuracy (specificity and sensitivity) fulfilling WHO target accuracy with a high sensitivity (93.2%-98.4%) detecting individuals with high viral load infections (Ct<20 and Ct<25). The test has also been independently verified in a 665-person study in Germany by FIND a global not-for-profit foundation and a WHO collaborating centre. The test was shown to demonstrate best-in-class performance with 100% specificity and 96.4% sensitivity (Cycle threshold <25) compared with laboratory PCR testing.


Further details of the study and the FIND report can be seen using the links below:




Omega Diagnostics Group PLC

Colin King, Chief Executive

via Walbrook PR

Kieron Harbinson, Group Finance Director




finnCap Ltd

Tel: 020 7220 0500

Geoff Nash/Edward Whiley (Corporate Finance)


Alice Lane (ECM)




Walbrook PR Limited

Tel: 020 7933 8780 or [email protected]

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t